Zynerba Pharmaceuticals Inc (ZYNE) Expected to Post Earnings of -$0.74 Per Share

Wall Street brokerages predict that Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will post earnings per share (EPS) of ($0.74) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Zynerba Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.84) and the highest estimate coming in at ($0.66). Zynerba Pharmaceuticals reported earnings per share of ($0.64) in the same quarter last year, which suggests a negative year over year growth rate of 15.6%. The company is expected to issue its next quarterly earnings results on Tuesday, August 7th.

On average, analysts expect that Zynerba Pharmaceuticals will report full year earnings of ($3.03) per share for the current year, with EPS estimates ranging from ($3.38) to ($2.78). For the next financial year, analysts anticipate that the firm will post earnings of ($2.69) per share, with EPS estimates ranging from ($3.12) to ($2.36). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings data on Tuesday, May 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.23).

ZYNE has been the subject of a number of recent analyst reports. Cantor Fitzgerald set a $20.00 price target on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, April 25th. Oppenheimer reaffirmed a “hold” rating on shares of Zynerba Pharmaceuticals in a report on Tuesday, May 8th. HC Wainwright set a $23.00 price target on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, March 6th. Seaport Global Securities reaffirmed a “buy” rating on shares of Zynerba Pharmaceuticals in a report on Tuesday, March 13th. Finally, ValuEngine raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $17.86.

In related news, major shareholder Michael Rapp acquired 5,885 shares of the stock in a transaction that occurred on Wednesday, May 30th. The stock was acquired at an average cost of $10.45 per share, for a total transaction of $61,498.25. The transaction was disclosed in a filing with the SEC, which is available through this link. 12.67% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its position in Zynerba Pharmaceuticals by 385.6% during the 1st quarter. JPMorgan Chase & Co. now owns 12,217 shares of the company’s stock worth $106,000 after purchasing an additional 9,701 shares in the last quarter. Alliancebernstein L.P. acquired a new position in Zynerba Pharmaceuticals in the 4th quarter valued at approximately $264,000. Alps Advisors Inc. increased its position in Zynerba Pharmaceuticals by 142.1% in the 1st quarter. Alps Advisors Inc. now owns 36,356 shares of the company’s stock valued at $316,000 after acquiring an additional 21,337 shares during the period. Wells Fargo & Company MN increased its position in Zynerba Pharmaceuticals by 19.6% in the 1st quarter. Wells Fargo & Company MN now owns 41,414 shares of the company’s stock valued at $360,000 after acquiring an additional 6,782 shares during the period. Finally, A.R.T. Advisors LLC increased its position in Zynerba Pharmaceuticals by 33.7% in the 1st quarter. A.R.T. Advisors LLC now owns 86,877 shares of the company’s stock valued at $754,000 after acquiring an additional 21,879 shares during the period. Institutional investors and hedge funds own 21.84% of the company’s stock.

Shares of Zynerba Pharmaceuticals traded down $0.82, reaching $11.57, on Friday, Marketbeat.com reports. 1,693,865 shares of the stock were exchanged, compared to its average volume of 226,248. Zynerba Pharmaceuticals has a one year low of $5.42 and a one year high of $20.73. The company has a market cap of $168.02 million, a PE ratio of -4.67 and a beta of 4.86.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply